19 Dec 2024
Editorial: Focus on Drug-Coated Balloons (DCB) in clinical practice
DCBs have undergone extensive development to meet the challenges of minimizing restenosis and maintaining vessel patency. Unlike stents, DCBs deliver an antiproliferative drug directly to the arterial wall without leaving a permanent implant. This approach has proven effective in treating small-vessel disease, in-stent restenosis, and de novo lesions, supported by a growing body of clinical evidence demonstrating sustained efficacy in reducing late lumen loss.
A core focus of The Essentials is to enhance understanding of DCB use in clinical practice. Through reports and webinars, the series covers the essential tools and techniques required for successful application.
We have a look back at the historical development, a detailed description of the current technology and best technique, a review of the existing evidence, a focussed article dealing with the problem of left main stent restenosis, and of course a glimpse into the future of this technology.
The webinar series on Drug-Coated Balloons (DCB) in coronary artery disease accompanying the reports offers a practical extension of these discussions. Led by global experts, these sessions delve into real-world applications, with a focus on treating native vessels, in-stent restenosis, and the indications chosen by expert users in daily practice.
By focusing on the clinical integration of DCBs, this initiative supports the ongoing effort to optimize outcomes and improve patient care in vascular interventions.
